Latest Information Update: 24 Nov 1995
At a glance
- Originator Yissum Research Development Company
- Developer BioCardia; Savient Pharmaceuticals; Yissum Research Development Company
- Class Antiplatelets
- Mechanism of Action Platelet aggregation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 24 Nov 1995 Discontinued-Preclinical for Thrombosis in Israel (Unknown route)
- 23 May 1995 Preclinical development for Thrombosis in Israel (Unknown route)
- 23 May 1995 Discontinued-Preclinical for Thrombosis in USA (Unknown route)